OSE Immunotherapeutics to Host KOL Webcast on Lusvertikimab's IBD Potential
Event summary
- OSE Immunotherapeutics will host a KOL webcast on September 2, 2026, to discuss lusvertikimab, its lead asset for Inflammatory Bowel Diseases (IBD).
- The webcast will feature experts Laurent Peyrin-Biroulet and Maia Kayal, alongside OSE's CEO Marc Le Bozec and CSO Aurore Morello.
- Topics include IL-7R biology, CoTiKis Phase 2 trial results in Ulcerative Colitis, and future development plans for Chronic Pouchitis.
The big picture
OSE Immunotherapeutics is positioning lusvertikimab as a key asset in the immuno-inflammation space, leveraging promising Phase 2 data to attract attention from KOLs and investors. The focus on IL-7R biology highlights a strategic push into targeted therapies for IBD, an area with significant unmet needs and high market potential. The webcast serves as a platform to validate the asset's clinical and commercial prospects.
What we're watching
- Clinical Validation
- How the CoTiKis Phase 2 trial results will influence lusvertikimab's pathway to market approval.
- Market Differentiation
- Whether lusvertikimab can carve out a niche in the competitive IBD treatment landscape.
- Development Strategy
- The pace at which OSE can advance lusvertikimab into Chronic Pouchitis trials following Ulcerative Colitis data.
Related topics